|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
ATE120761T1
(de)
|
1987-05-21 |
1995-04-15 |
Creative Biomolecules Inc |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
FI102355B
(fi)
|
1988-02-11 |
1998-11-30 |
Squibb Bristol Myers Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
DE122004000008I1
(de)
|
1991-06-14 |
2005-06-09 |
Genentech Inc |
Humanisierter Heregulin Antikörper.
|
|
EP1136556B1
(en)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Method of producing multivalent antigen-binding proteins
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
AU4116793A
(en)
|
1992-04-24 |
1993-11-29 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US7625697B2
(en)
|
1994-06-17 |
2009-12-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for constructing subarrays and subarrays made thereby
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
|
US6653445B1
(en)
|
1997-01-21 |
2003-11-25 |
Human Genome Sciences, Inc. |
Human CCV polypeptides
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US20030065156A1
(en)
|
1997-12-23 |
2003-04-03 |
Williams Lewis T. |
Novel human genes and gene expression products I
|
|
DK1071710T4
(da)
|
1998-04-15 |
2011-12-12 |
Merck Serono Biodevelopment |
Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma
|
|
US6264949B1
(en)
|
1998-09-29 |
2001-07-24 |
Mount Sinai School Of Medicine Of New York University |
Noninvasive agents for diagnosis and prognosis of the progression of fibrosis
|
|
WO2001057188A2
(en)
|
2000-02-03 |
2001-08-09 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
|
US20020137160A1
(en)
|
1998-12-17 |
2002-09-26 |
Byatt John C |
Nucleic acid and other molecules associated with lactation and muscle and fat deposition
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7160694B2
(en)
|
1999-06-14 |
2007-01-09 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding TANGO405 and functional fragments and uses thereof
|
|
AU6069300A
(en)
|
1999-07-02 |
2001-01-22 |
Chiron Corporation |
Novel human genes and gene expression products
|
|
EP1074617A3
(en)
|
1999-07-29 |
2004-04-21 |
Research Association for Biotechnology |
Primers for synthesising full-length cDNA and their use
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
JP2003533968A
(ja)
|
1999-09-03 |
2003-11-18 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
|
|
AU6063900A
(en)
|
1999-09-10 |
2001-04-10 |
Millennium Pharmaceuticals, Inc. |
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
|
|
CA2384713A1
(en)
|
1999-09-29 |
2001-04-05 |
Human Genome Sciences, Inc. |
Colon and colon cancer associated polynucleotides and polypeptides
|
|
WO2001051628A2
(en)
|
2000-01-14 |
2001-07-19 |
Millennium Pharmaceuticals, Inc. |
Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
|
WO2001055309A2
(en)
|
2000-01-31 |
2001-08-02 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
US20030013649A1
(en)
|
2000-01-31 |
2003-01-16 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
|
US20020042386A1
(en)
|
2000-01-31 |
2002-04-11 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
|
AU2001241541A1
(en)
|
2000-02-17 |
2001-08-27 |
Millennium Predictive Medicine, Inc. |
Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
|
|
CN1169954C
(zh)
|
2000-03-09 |
2004-10-06 |
上海市肿瘤研究所 |
编码具有抑制癌细胞生长功能的人蛋白的多核苷酸
|
|
US20030165831A1
(en)
|
2000-03-21 |
2003-09-04 |
John Lee |
Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
|
|
US6436703B1
(en)
|
2000-03-31 |
2002-08-20 |
Hyseq, Inc. |
Nucleic acids and polypeptides
|
|
AU2001274888A1
(en)
|
2000-05-19 |
2001-12-03 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
WO2001094629A2
(en)
|
2000-06-05 |
2001-12-13 |
Avalon Pharmaceuticals |
Cancer gene determination and therapeutic screening using signature gene sets
|
|
EP1305450A2
(en)
|
2000-07-28 |
2003-05-02 |
Compugen Inc. |
Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
|
|
WO2002028902A2
(en)
|
2000-10-05 |
2002-04-11 |
Immunex Corporation |
Nectin polypeptides, polynucleotides, methods of making and use thereof
|
|
US20040029114A1
(en)
|
2001-01-24 |
2004-02-12 |
Eos Technology, Inc. |
Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
|
|
JP2005503760A
(ja)
|
2001-01-24 |
2005-02-10 |
プロテイン デザイン ラブス， インコーポレイテッド |
乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
|
|
WO2002060317A2
(en)
|
2001-01-30 |
2002-08-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of pancreatic cancer
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
AU2002338431A1
(en)
|
2001-04-04 |
2002-11-05 |
Quark Biotech, Inc. |
Sequence characteristics of bladder cancer
|
|
AU2002309583A1
(en)
|
2001-04-18 |
2002-11-05 |
Protein Desing Labs, Inc. |
Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
|
US6794501B2
(en)
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
|
JP2004528046A
(ja)
|
2001-06-05 |
2004-09-16 |
エクセリクシス・インコーポレイテッド |
ｐ５３経路のモディファイヤーとしてのＤＧＫｓおよび使用方法
|
|
US7189507B2
(en)
|
2001-06-18 |
2007-03-13 |
Pdl Biopharma, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
|
WO2002102235A2
(en)
|
2001-06-18 |
2002-12-27 |
Eos Biotechnology Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
|
US20030099974A1
(en)
|
2001-07-18 |
2003-05-29 |
Millennium Pharmaceuticals, Inc. |
Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
|
|
ES2281528T3
(es)
|
2001-07-19 |
2007-10-01 |
Nymox Corporation |
Peptidos eficaces en el tratamiento de tumores y otros estados que requieren la eliminacion o destruccion de celulas.
|
|
EP2153843B1
(en)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7226594B2
(en)
|
2001-11-07 |
2007-06-05 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
WO2003042661A2
(en)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US20030232350A1
(en)
|
2001-11-13 |
2003-12-18 |
Eos Biotechnology, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003245488A1
(en)
|
2002-06-13 |
2003-12-31 |
Regulome Corporation |
Functional sites
|
|
US7595048B2
(en)
|
2002-07-03 |
2009-09-29 |
Ono Pharmaceutical Co., Ltd. |
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
|
|
PT2357006E
(pt)
|
2002-07-31 |
2016-01-22 |
Seattle Genetics Inc |
Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
|
|
AU2008202217B2
(en)
|
2002-08-16 |
2012-07-26 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer
|
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
CA2496923A1
(en)
|
2002-08-29 |
2004-03-11 |
University Of Massachusetts |
Utilization of emulsion interface engineering to produce oxidatively stable lipid delivery systems
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
EP1732600A2
(en)
|
2004-03-26 |
2006-12-20 |
Pfizer Products Incorporated |
Uses of anti-ctla-4 antibodies
|
|
WO2005111076A1
(en)
|
2004-05-12 |
2005-11-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nectin 4 (n4) as a marker for cancer prognosis
|
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
JP2008521411A
(ja)
*
|
2004-11-30 |
2008-06-26 |
キュラジェン コーポレイション |
Ｇｐｎｍｂに対する抗体およびその使用
|
|
CN101500590A
(zh)
|
2005-03-31 |
2009-08-05 |
阿根西斯公司 |
与161p2f10b蛋白结合的抗体和相关分子
|
|
BRPI0609655A2
(pt)
|
2005-03-31 |
2010-03-16 |
Agensys Inc |
anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
RS54271B1
(sr)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
WO2008007648A1
(fr)
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
|
JP5394246B2
(ja)
|
2007-03-30 |
2014-01-22 |
ジェネンテック， インコーポレイテッド |
抗体及びイムノコンジュゲートとこれらの使用方法
|
|
NZ582150A
(en)
|
2007-06-18 |
2012-08-31 |
Msd Oss Bv |
Antibodies to human programmed death receptor pd-1
|
|
DK2234600T3
(da)
*
|
2007-12-21 |
2014-09-08 |
Hoffmann La Roche |
Antistofformulering
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
MX2011003195A
(es)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
|
HRP20170908T1
(hr)
|
2008-12-09 |
2017-09-22 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
|
CA3150199C
(en)
|
2009-01-09 |
2025-07-22 |
Seagen Inc. |
WEEKLY DOSING REGIMEN FOR ANTI-CD30 ANTIBODY CONJUGATIONS VC-PAB-MMAE - MEDICINE
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
WO2011082400A2
(en)
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
|
US8758758B1
(en)
|
2010-01-08 |
2014-06-24 |
Seattle Genetics, Inc. |
Post-relapse treatment of CD30 expressing lymphomas
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
AU2011312417B2
(en)
|
2010-09-29 |
2015-08-20 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
JP6117921B2
(ja)
|
2012-07-12 |
2017-04-19 |
ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド |
細胞毒性剤と細胞結合受容体との共役体
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US20150292030A1
(en)
|
2012-11-27 |
2015-10-15 |
Board Of Regents, The University Of Texas System |
Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
|
|
US10023916B2
(en)
|
2013-04-15 |
2018-07-17 |
Regeneron Pharmaceuticals, Inc. |
Markers of tumor cell response to anti-cancer therapy
|
|
HRP20210122T1
(hr)
|
2013-05-02 |
2021-04-16 |
Anaptysbio, Inc. |
Protutijela usmjerena protiv programirane smrti-1 (pd-1)
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
SG11201601844TA
(en)
|
2013-09-13 |
2016-04-28 |
Beigene Ltd |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
|
SG11201604738TA
(en)
|
2013-12-12 |
2016-07-28 |
Shanghai Hengrui Pharm Co Ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
SG10201913696YA
(en)
|
2014-07-18 |
2020-03-30 |
Advaxis Inc |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
|
GB201419185D0
(en)
|
2014-10-28 |
2014-12-10 |
Adc Biotechnology Ltd |
Method of synthesising ADCs using affinity resin
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
WO2018017714A1
(en)
|
2016-07-20 |
2018-01-25 |
Aerpio Therapeutics, Inc. |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
TW202508642A
(zh)
|
2016-12-12 |
2025-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
|
|
US11292837B2
(en)
|
2017-06-05 |
2022-04-05 |
Agensys, Inc. |
Nectin-4 binding proteins and methods of use thereof
|
|
KR20240167101A
(ko)
|
2017-09-07 |
2024-11-26 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 넥틴4에 결합하는 단백질
|
|
KR20200135841A
(ko)
|
2018-03-23 |
2020-12-03 |
시애틀 지네틱스, 인크. |
고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
|
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
|
CN111423512B
(zh)
|
2019-01-10 |
2024-01-05 |
北京比洋生物技术有限公司 |
阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
|
|
EP4007602A1
(en)
|
2019-08-01 |
2022-06-08 |
Incyte Corporation |
A dosing regimen for an ido inhibitor
|
|
TWI873167B
(zh)
|
2019-08-13 |
2025-02-21 |
美商艾澤西公司 |
以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症
|
|
CA3162282A1
(en)
|
2019-11-25 |
2021-06-03 |
Agensys, Inc. |
Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
|
CA3185666A1
(en)
|
2020-06-19 |
2021-12-23 |
Agensys, Inc. |
Markers for use in methods for treating cancers with antibody drug conjugates (adc)
|
|
IL301163A
(en)
|
2020-09-17 |
2023-05-01 |
Agensys Inc |
Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
|
MX2023004089A
(es)
|
2020-10-11 |
2023-06-28 |
Agensys Inc |
Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.
|
|
JP2024534012A
(ja)
|
2021-08-13 |
2024-09-18 |
アジェンシス，インコーポレイテッド |
１９１ｐ４ｄ１２タンパク質に結合する抗体薬物複合体（ａｄｃ）を用いた非筋肉浸潤性膀胱癌（ｎｍｉｂｃ）の治療方法
|
|
TW202333801A
(zh)
|
2022-01-05 |
2023-09-01 |
美商艾澤西公司 |
以結合至191p4d12蛋白質之抗體藥物結合物(adc)治療肌肉侵襲性尿路上皮癌或肌肉侵襲性膀胱癌之方法
|
|
CN119907684A
(zh)
|
2022-07-25 |
2025-04-29 |
艾更斯司股份有限公司 |
用结合191p4d12蛋白的抗体药物偶联物(adc)与帕博利珠单抗组合治疗患有局部晚期或转移性尿道上皮癌的患者的方法
|